We are live on ! Find out more
BC

Boxer Capital Portfolio holdings

AUM $2.04B
1-Year Est. Return 108.39%
This Fund
S&P 500
This Quarter Est. Return
+12.09%
1 Year Est. Return
+108.39%
3 Year Est. Return
+261.8%
5 Year Est. Return
+1,135.09%
10 Year Est. Return
–
AUM
$2.04B
AUM Growth
+$139M
Cap. Flow
+$195M
Cap. Flow %
9.6%
Top 10 Hldgs %
52.83%
Holding
78
New
7
Increased
4
Reduced
2
Closed
3

Top Buys

Rank Stock Value
1
SRPT icon
Sarepta Therapeutics
SRPT
+$101M
2
SGEN
Seagen Inc. Common Stock
SGEN
+$32.1M
3
RVMD icon
Revolution Medicines
RVMD
+$17.2M
4
IOVA icon
Iovance Biotherapeutics
IOVA
+$15.2M
5
ELVN icon
Enliven Therapeutics
ELVN
+$14.5M

Top Sells

Rank Stock Value
1
GERN icon
Geron
GERN
+$19.6M
2
ARVN icon
Arvinas
ARVN
+$5.13M
3
FATE icon
Fate Therapeutics
FATE
+$4.53M
4
THRX
Theseus Pharmaceuticals, Inc. Common Stock
THRX
+$638K
5
BLCM
Bellicum Pharmaceuticals, Inc.
BLCM
+$41K

Sector Composition

Rank Sector Weight
1 Healthcare 99.75%
2 Financials 0.25%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CNTA
51
DELISTED
Centessa Pharmaceuticals
CNTA
$4.82M 0.24%
1,251,137
– –
TSVT
52
DELISTED
2seventy bio
TSVT
$4.69M 0.23%
459,836
– –
RNAC icon
53
Cartesian Therapeutics
RNAC
$229M
$4.57M 0.22%
109,469
– –
CABA icon
54
Cabaletta Bio
CABA
$437M
$4.47M 0.22%
540,000
– –
GOSS icon
55
Gossamer Bio
GOSS
$82.9M
$4.21M 0.21%
3,336,928
– –
PRLD icon
56
Prelude Therapeutics
PRLD
$366M
$3.98M 0.2%
+699,047
New +$4.26M
BDTX icon
57
Black Diamond Therapeutics
BDTX
$96.8M
$3.81M 0.19%
2,014,858
– –
KNTE
58
DELISTED
Kinnate Biopharma Inc. Common Stock
KNTE
$3.19M 0.16%
510,000
– –
THRX
59
DELISTED
Theseus Pharmaceuticals, Inc. Common Stock
THRX
$3.11M 0.15%
350,000
-65,000
-16% -$638K
FATE icon
60
Fate Therapeutics
FATE
$286M
$2.85M 0.14%
500,000
-750,000
-60% -$4.53M
IRON icon
61
Disc Medicine
IRON
$2.94B
$2.75M 0.14%
130,000
– –
MIST icon
62
Milestone Pharmaceuticals
MIST
$138M
$2.75M 0.14%
698,861
– –
BCEL
63
DELISTED
Atreca, Inc. Class A Common Stock
BCEL
$2.51M 0.12%
2,202,333
– –
DBVT
64
DBV Technologies
DBVT
$799M
$2.45M 0.12%
145,000
– –
THRD
65
DELISTED
Third Harmonic Bio
THRD
$2.35M 0.12%
570,417
– –
NGM
66
DELISTED
NGM Biopharmaceuticals, Inc. Common Stock
NGM
$2.04M 0.1%
500,000
– –
EQRX
67
DELISTED
EQRx, Inc. Common Stock
EQRX
$1.94M 0.1%
1,000,000
– –
BCAB icon
68
BioAtla
BCAB
$5.46M
$1.84M 0.09%
13,727
– –
MREO
69
Mereo BioPharma
MREO
$54.7M
$1.59M 0.08%
2,250,000
– –
TCRT icon
70
Alaunos Therapeutics
TCRT
$4.59M
$945K 0.05%
10,000
– –
LITS
71
Lite Strategy Inc
LITS
$32.8M
$667K 0.03%
145,655
– –
TARA icon
72
Protara Therapeutics
TARA
$220M
$655K 0.03%
209,227
– –
VERU icon
73
Veru
VERU
$36M
$403K 0.02%
34,730
– –
NUVB.WS
74
DELISTED
Nuvation Bio Inc Warrants
NUVB.WS
$32K ﹤0.01%
266,666
– –
SRZNW icon
75
Surrozen Inc Warrant
SRZNW
$69.7K
$4K ﹤0.01%
66,666
– –
1 2
3
4

Similar funds

FTDI
First Trust Direct Indexing Boston, Massachusetts $1.87B AUM 43.63% 1-Year Est. Return
CIM
Contrarius Investment Management St. Helier, Jersey $1.76B AUM 35.87% 1-Year Est. Return
PRO
Pensioenfonds Rail & OV Utrecht, Netherlands $1.44B AUM 23.73% 1-Year Est. Return
GFS
GYL Financial Synergies West Hartford, Connecticut $1.33B AUM 34.46% 1-Year Est. Return
ECM
Ensemble Capital Management San Francisco, California $1.18B AUM 41.81% 1-Year Est. Return
CIP
Chartwell Investment Partners Berywn, Pennsylvania $2.91B AUM 40.48% 1-Year Est. Return
SEC
Seven Eight Capital New York $1.11B AUM 29.48% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

Boxer Capital's Q1 2023 Portfolio in Review

As of Q1 2023, Boxer Capital held 78 positions worth $2.04B, up 7.3% from $1.9B the previous quarter. Its ten largest holdings account for 53% of the portfolio.

Boxer Capital deployed $195M of net new capital in Q1 2023, opening 7 new positions and adding to 4 existing holdings. Its largest new stake was Sarepta Therapeutics: 775,000 shares worth $107M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was Fate Therapeutics, an estimated $4.53M trimmed.

  • Boxer Capital's largest Q1 2023 buy was Sarepta Therapeutics: 775,000 shares worth $107M.
  • Boxer Capital added most to Revolution Medicines in Q1 2023, an estimated $17.2M increase.
  • Boxer Capital's biggest Q1 2023 reduction was Fate Therapeutics, cutting an estimated $4.53M.
  • Boxer Capital fully exited Geron in Q1 2023, selling an estimated $19.6M.
  • Boxer Capital's ten largest holdings make up 53% of its $2.04B portfolio in Q1 2023.
  • Boxer Capital opened 7 new positions and closed 3 in Q1 2023.
  • Boxer Capital's portfolio value rose 7.3% quarter-over-quarter to $2.04B.

Based on Boxer Capital's 13F filing for Q1 2023, filed 15 May 2023.